Metastatic Cancer Clinical Trials

45 studies are recruiting for metastatic cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

   This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sylvester Comprehensive Cancer Center - Miami, Miami, Florida

   Locations

   17 in total

   Run by

   Aulos Bioscience, Inc.

   See if you can join NCT05267626 on ClinicalTrials.gov

2. Prospective Validation of a Points Score System Predicting 30-day Survival

   This is a one-stage single-arm phase II clinical trial designed to prospectively test the survival prediction tool as developed by Lee et al on patients referred to radiation oncology for palliative treatments. Survival prediction score based on objective data including laboratory values, attendanc…

   Stage

   Not phased

   Ages

   18 and older

   Site

   IU Health West, Avon, Indiana

   Locations

   3 in total

   Run by

   Indiana University

   See if you can join NCT05100342 on ClinicalTrials.gov

3. Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

   To learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05475171 on ClinicalTrials.gov

4. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of San Diego Moores Cancer Center, La Jolla, California

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

5. Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas

   This is a Phase I study to evaluate the safety and efficacy of the [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of California Davis Comprehensive Cancer Center, Sacramento, California

   Run by

   University of California, Davis

   See if you can join NCT06389123 on ClinicalTrials.gov

6. Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.

   Unblinded, randomized study of 5-fraction LATTICE radiotherapy (20 Gy with an SIB to 66.7 Gy in 5 fractions) versus moderately dose-escalated palliative radiation (25 Gy in 5 fractions)

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Stanford University, Palo Alto, California

   Run by

   Stanford University

   See if you can join NCT07594431 on ClinicalTrials.gov

7. PRE-ISPY Phase I/II Oncology Platform Program

   PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama

   Locations

   10 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT05868226 on ClinicalTrials.gov

8. Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers

   This phase I study tests the safety, side effects, and best dose of Ac225-DOTA-M5A in treating patients with CEA positive colorectal cancer that has spread to other places in the body (advanced). Ac225-DOTA-M5A is a humanized monoclonal anti-CEA antibody, linked to a radioactive agent called actini…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT05204147 on ClinicalTrials.gov

9. Biomarkers to Detect Endocrine Therapy Resistance

   This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy. 18F-fluorofuranylnorprogesterone Positron Emission Tomography/Computed Tomography (FFNP-PET/CT…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UW Carbone Cancer Center, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT06067503 on ClinicalTrials.gov

10. Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer

    Participants with metastatic cancer who are taking anti-PD-1 or anti-PD-L1 therapy will be enrolled to assess the safety of and find the optimal dose for radioactive imaging agents and to explore whether these agents will make current drug therapies work better. Up to 60 participants will be enroll…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UW Carbone Cancer Center, Madison, Wisconsin

    Run by

    University of Wisconsin, Madison

    See if you can join NCT07197671 on ClinicalTrials.gov

11. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic, Phoenix, Arizona

    Locations

    33 in total

    Run by

    Parabilis Medicines, Inc.

    See if you can join NCT05919264 on ClinicalTrials.gov

12. A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

    Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participan…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05859074 on ClinicalTrials.gov

13. A Study of MGC026 in Participants With Advanced Solid Tumors

    The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort ex…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Angeles Clinic and Research Institute, Los Angeles, California

    Locations

    12 in total

    Run by

    MacroGenics

    See if you can join NCT06242470 on ClinicalTrials.gov

14. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    82 in total

    Run by

    Artios Pharma Ltd

    See if you can join NCT04657068 on ClinicalTrials.gov

15. Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

    This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma (RCC) with bone metastases whose disease has advanced on 1-3 prior lines of therapy, including at least one immune oncology-based (IO) ther…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Kelly Fitzgerald, MD

    See if you can join NCT07043608 on ClinicalTrials.gov

16. SLV-154 Treatment of Advanced Cancers

    This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Hoag Memorial Hospital Presbyterian, Newport Beach, California

    Locations

    10 in total

    Run by

    Solve Therapeutics

    See if you can join NCT06771219 on ClinicalTrials.gov

17. A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer

    To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare. Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuatio…

    Stage

    Not phased

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06693687 on ClinicalTrials.gov

18. PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

    This is a hybrid decentralized, single-arm, interventional study designed to evaluate the impact of precision medicine navigation and reflexive expert review of next-generation sequencing (NGS) for patients with stage IV solid tumor malignancies (breast, lung, colorectal, and bladder cancers). The …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06896162 on ClinicalTrials.gov

19. (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

    This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent …

    Stage

    Phase 3

    Ages

    18 and older

    Site

    MedStar Washington Hospital Center, Washington D.C., District of Columbia

    Locations

    126 in total

    Run by

    Cogent Biosciences, Inc.

    See if you can join NCT05208047 on ClinicalTrials.gov

20. Evaluating Disparities in Precision Oncology

    This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

    Run by

    Indiana University

    See if you can join NCT06081517 on ClinicalTrials.gov

21. Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

    The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurately predict OS and the use of this metric in other settings …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    VA Greater Los Angeles Healthcare System, Los Angeles, California

    Locations

    12 in total

    Run by

    Sun Pharmaceutical Industries Limited

    See if you can join NCT05422911 on ClinicalTrials.gov

22. E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

    This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TC…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Locations

    3 in total

    Run by

    Christian Hinrichs

    See if you can join NCT05686226 on ClinicalTrials.gov

23. MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

    This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of MEM-288 in patients with advanced solid tumors. Eligible sub…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    2 in total

    Run by

    Memgen, Inc.

    See if you can join NCT05076760 on ClinicalTrials.gov

24. Imaging of Solid Tumors Using FAP-2286

    This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Thomas Hope

    See if you can join NCT04621435 on ClinicalTrials.gov

25. Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

    The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma). It will also help the researchers to learn more about the safety of givastomig. The main questions it aims to answer…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    I-Mab Site 1016, Goodyear, Arizona

    Locations

    6 in total

    Run by

    I-Mab Biopharma US Limited

    See if you can join NCT07432295 on ClinicalTrials.gov